Background The best-known cause of intolerance to fluoropyrimidines is dihydropyrimidine
dehydrogenase (DPD) deficiency, which can result from deleterious polymorphisms in the …

Both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch
Pharmacogenetics Working Group provide therapeutic recommendations for well‐known …

The purpose of this guideline is to provide information for the interpretation of clinical
dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to …

Background Fluoropyrimidine treatment can result in severe toxicity in up to 30% of patients
and is often the result of reduced activity of the key metabolic enzyme dihydropyrimidine …

Despite advances in the field of pharmacogenetics (PGx), clinical acceptance has remained
limited. The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx …

Abstract Purpose For over 50 years, 5-FU has played a critical role in the systemic
chemotherapy of cancer patients. 5-FU serves as the main backbone of combination …

Fluorouracil (5-FU) and capecitabine (CAP) are among the most frequently prescribed
anticancer drugs. They are inactivated in the liver by the enzyme dihydropyrimidine …

Fluoropyrimidines are widely used in the treatment of several types of solid tumors. Although
most often well tolerated, severe toxicity is encountered in~ 20–30% of the patients …

5‐Fluorouracil (5‐FU) is dosed by body surface area, a practice unable to reduce the
interindividual variability in exposure. Endorsed by the International Association of …

The fluoropyrimidine anticancer drugs, especially 5-fluorouracil (5-FU) and capecitabine,
are frequently prescribed for several types of cancer, including breast, colorectal, head and …